In February, the New England Journal of Medicine published a report that found the use of brain-imaging technologies in cancer treatment was associated with a 22 percent increased risk of death.
The findings were backed up by the United States Surgeon General, who in June 2015 reported that the use, among other things, of brain scans was associated for the first time with a 15 percent increased death rate.
The Surgeon-General’s report also said there was a 1.4 percent increased chance of death from brain cancer, but only for the elderly.
The same Surgeon Generals report found that the brain scan had a greater risk of causing death than a CT scan of the brain.
In addition, a study in the Journal of the American Medical Association in 2016 found that brain imaging had an increased risk for a patient who died of cancer, and that the risk was greater for women who underwent brain surgery than for men who did not.
In an effort to find a more affordable way to treat brain cancer and other brain disorders, several research groups in recent years have been looking into alternative imaging technologies.
The National Cancer Institute recently launched the Brain Imaging Technologies Program, which seeks to develop and support brain imaging technologies that are inexpensive and can be used in research for cancer treatment and other health issues.
One of the first researchers to be tapped into the program is the University of Pittsburgh Medical Center.
The university’s Brain Imaging Technology Research and Development Institute has been working with neuroscientists from around the world to develop a new generation of neuroimaging technology that will allow researchers to better study brain tumors.
The institute has recently begun work on the NeuroTrip device, which is based on the technology that was used in the earlier phase of the project.
The team plans to begin using the NeuroCAT system, a prototype of the Neurotrip system, in 2018.
The NeuroTram is designed to measure blood flow and oxygenation in the brain of an individual with cancer and then transfer that data to a computer.
The system will also be able to generate images that can be viewed by researchers who are on the ground at the patient’s site.
NeuroTrams are designed to use a technology known as neuroelectroencephalography (neuroelectrode), which was developed to monitor the activity of neurons in the cortex, the region of the cerebral cortex where most of the thinking and the thinking processes take place.
NeuroElectrode has been developed to allow scientists to record brain activity, and it has been shown to be effective in tracking brain activity in the brains of cancer patients.
NeuroCATS are currently undergoing a clinical trial and are slated to go on sale later this year.
The researchers are also developing a prototype for the NeuroMATS device, a device that uses EEG technology to capture brain activity to study the brain in a patient.
NeuroMAT is being developed in collaboration with the University at Buffalo, Buffalo State University, and University of Pennsylvania.
In order to conduct these experiments, researchers will use NeuroTras, NeuroCats, and NeuroMats to monitor a patient’s brain activity and then record brain waves using electrodes placed on the patient.
The devices will be able capture the brain activity of a patient and then send those brain waves back to a lab, where researchers will be using a computer to analyze the data.
Researchers will also use the data to develop new imaging techniques that will be used to predict the course of cancer.
Brain-imagining technologies have been used to study brain tumor progression in the past, but in the early days of the neuroimagination era, it was often expensive and cumbersome to use these technologies.
Brain imaging technology has improved over time, and more research has been done to find effective ways to use it.
Researchers say it is time to make a conscious decision about which brain imaging technology is the most appropriate to use in treating cancer.
The first steps in the development of a better imaging technology are typically taking the data from the patient and the person’s brain and combining it with information about their environment.
This will give researchers a better understanding of how a person might be doing, and can help predict the most effective treatments.
NeuroImaging Technologies will be available for use in the United Kingdom in the first half of 2019.
The next step is to work with leading academic institutions around the globe to develop the technology and begin using it in clinical trials.
The American Institute of Cancer Research (AICR) is currently working with several companies to begin trials in the U.S. to develop NeuroTrap and NeuroCatalites, a novel imaging technology that uses electrodes implanted in the patient to record the brain waves of a person’s seizures.
The AICR is working with a number of companies to help develop the Neurotram device.
These companies are working with universities and hospitals around the country to develop prototypes for NeuroTRAB and NeuroTMATS. This